FTY720 in immuno-regenerative and wound healing technologies for muscle, epithelial and bone regeneration

In 2010, the FDA approved the administration of FTY720, S1P lipid mediator, as a therapy to treat relapsing forms of multiple sclerosis. FTY720 was found to sequester pro-inflammatory lymphocytes within the lymph node, preventing them from causing injury to the central nervous system due to inflamma...

Full description

Bibliographic Details

Published in:	Frontiers in Physiology
Main Authors:	Monica Behara, Steven Goudy
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Subjects:	regenerative medicine tissue engineering immunomodulation FTY720 multiple sclerosis wound healing
Online Access:	https://www.frontiersin.org/articles/10.3389/fphys.2023.1148932/full